Key takeaways

• A document presented at the 2026 CCMG/Garrod conference connects phenylketonuria to a broader burden than blood Phe alone: comorbidities, restriction of natural protein, and quality of life.

• As we age with PKU, the question is not only how to control a blood test result, but how to preserve overall health.

• Sephience does not solve everything, but if it allows some people to lower their Phe and increase natural protein intake, it could reduce an important part of the long-term burden.

Disclaimer: I am not a physician. This text reflects my personal experience with phenylketonuria and my reading of the available data. It does not replace advice from a metabolic team. Any change to treatment, diet, or natural protein intake should be made with a healthcare professional.

When we talk about phenylketonuria, we almost always come back to the same number: the level of phenylalanine (Phe) in the blood. That makes sense. Phe is at the center of the disease. It guides decisions, dietary adjustments, treatments, and even the mental state of the week. But the older I get, the more I wonder whether this number, as important as it is, only tells part of the story.

A document presented at the 2026 joint conference of the Canadian College of Medical Geneticists and Garrod struck me for that reason. It does not speak only about Phe as a laboratory result. It tries to connect several dimensions of PKU: elevated phenylalanine levels, neurocognitive symptoms, comorbidities, chronic restriction of natural protein, and quality of life. The document comes from PTC Therapeutics, so it should be read with the necessary caution when a pharmaceutical company produces a review in its own field. But the question it raises matters: what does a whole life with PKU do?

The document, one of many reviewed and accepted at this medical/scientific meeting, reminds us that comorbidities are common in PKU and may be connected to two realities that move together: on one side, Phe levels that are too high; on the other, the restriction of natural protein required to control them. It mentions issues such as anemia, overweight, obesity, osteoporosis, renal insufficiency, kidney stones, some digestive disorders, cardiovascular disease, diabetes, mood disorders, and cognitive or executive-function difficulties. This list should not be read as an individual sentence. These are not certainties for every person. But they are signals that force us to look at PKU as a lifelong condition, along with other conditions affecting many, not only as a Phe problem to manage meal by meal.

I do not read this in an abstract way. I read it as someone who lives with PKU, who has a daughter (without PKU), who has worked very hard to build a good life, and who wants to stay here for a long time. I want to be able to play and talk with my daughter and run with my grandchildren. I would like to age in good health, keep my mind, my independence, my energy, and my ability to be present. But when you live with a metabolic disease from birth, you need to think beyond the next blood test. And right now, no one really knows what will happen to PKU patients with elevated Phe levels when they reach 80 years old or older.

This is where comorbidities become very concrete. Obesity, insulin resistance, inflammation, metabolic problems, age-related muscle loss: these are not topics separate from PKU. They are part of the same body. A person with PKU can also age, gain weight, lose muscle, sleep less well, become more metabolically vulnerable, or see their cognitive health become more fragile. PKU does not explain everything, and we should not attribute every health problem to it. But it would be too simple to say that a whole life of dietary restriction, sometimes elevated Phe, and dependence on specialized products has no effect on overall health.

Sarcopenia, for example, is not at the center of the document, but it is at the center of my concerns. As we age, losing muscle is not about appearance. It is about losing reserve. It means having more difficulty walking, recovering, staying independent, getting through an illness or a harder period. In the general population, there is more and more discussion about the importance of protein, resistance training, and maintaining muscle mass with age. In PKU, that discussion is more complicated, because natural, muscle-building protein is precisely what we restrict.

Protein substitutes are essential. They have allowed generations of people with PKU to develop, function, work, and live a life. But in real life, it is not the same thing as a freer, more varied, more normal diet with normal nutrition. It is not only a question of nutrition on paper. It is also a question of satiety, pleasure, simplicity, mental fatigue, and one’s relationship with food. Many people with PKU know the feeling of always having to compensate, always plan, always explain, sometimes always be hungry, or never quite eat like everyone else. This constant management has heavy social and cognitive impacts.

This is the context in which Sephience becomes interesting to me. Not as a miracle solution. Not as a promise that everything disappears. Not as a medication that replaces medical follow-up. But as a possibility to reduce the burden in two places at once: Phe and dietary restriction.

I have already written about the comparison between Sephience and Kuvan in my previous article on the burden of the low-phenylalanine diet. The essential point remains the same: the AMPLIPHY study directly compares sepiapterin, the active ingredient in Sephience, with sapropterin, known as Kuvan. In people who responded to sepiapterin, Sephience reduced Phe more than the maximum approved dose of sapropterin. This matters because Kuvan has helped some people, but it has never transformed life for everyone. For many people with PKU, diet has remained at the center of treatment, with all the burden that comes with it.

But for me, the most important question comes after the Phe reduction: what can a better reduction in Phe make possible in real life? This is where the APHENITY extension data become relevant. In that study, some people treated with sepiapterin were able to significantly increase their dietary Phe intake, meaning natural protein, while being monitored. The nuance matters. Sephience does not mean abandoning the diet. The Canadian Sephience product monograph states that the treatment should be used with a phenylalanine-restricted diet, as recommended by a healthcare professional, and that response must be assessed individually.

But increasing natural protein in PKU is not a minor comfort detail. It is potentially a life less organized around the disease. Fewer calculations. Fewer specialized products. Fewer separate meals. Less mental load. Maybe better satiety. Maybe a diet that is denser, simpler, and more sustainable. And over time, that margin can become important.

The conference document does not prove that Sephience will prevent obesity, insulin resistance, osteoporosis, kidney problems, or sarcopenia. That would go too far. Rather, it shows that PKU needs to be considered more globally. It shows that comorbidities exist, that the dietary burden is real, that quality of life is affected, and that restricting natural protein for a lifetime is not simply a medical strategy without consequences. That is already a lot.

Partager

I think this is where the discussion around Sephience should be situated. Not only in a logic of a medication that is more effective than Kuvan. Not only in a short-term pricing logic. And not in an overly quick promise of cognitive or physical improvement either. We should instead ask what better metabolic control and greater natural protein tolerance could change in our overall wellbeing over several years.

PKU often forces us to think in days:

• How much Phe today?

• What blood result this week?

• How much natural protein in this meal?

But aging with PKU forces us to think in decades:

• What cognitive health at 70?

• What strength at 80?

• What independence?

• What metabolic risk?

• What economic burden for the healthcare system?

• What quality of life for families?

• What ability to remain present for the people we love?

That is probably what touches me most in these data. They remind me that I do not only want to survive with PKU. I want to age with as much capability and reserve as possible. Cognitive reserve, muscle reserve, metabolic reserve, emotional reserve. I want to keep my place in my family. I want to be there for my daughter. I want, if I get that chance, to be a present, healthy, and fit grandfather.

Sephience does not guarantee that. No treatment can guarantee that. But if it allows some people to better control their Phe while increasing natural protein intake, then its importance is not limited to a better value in a table. It could help make life with PKU a little less organized around restriction, and a little more oriented toward long-term health.

And for me, that is where the subject becomes truly human. The question is not only whether Sephience is impressive. The question is whether it can give more margin to people who have lived with PKU from the beginning. More margin to eat. More margin to think. More margin to age. More margin to live.

Laissez un commentaire.

Key takeaways

• The low-phenylalanine diet remains the historical foundation of phenylketonuria treatment, but it places a significant cognitive, psychological, and social burden on patients throughout life.

• Kuvan has helped some patients better control their Phe levels, but Sephience appears to lower phenylalanine more than sapropterin in people who respond to it and more people respond to Sephience than Kuvan.

• Sephience should not be evaluated as a direct cognitive promise: its main effect is lowering Phe, and better long-term metabolic control may, over time, create better conditions for the brain, nutrition, and quality of life.

Disclaimer: The information presented here reflects my personal experience with phenylketonuria and my own research. It does not replace professional medical advice. Always consult a healthcare professional before making changes to your diet or starting a physical activity program.

The original and classic treatment for phenylketonuria has rested for decades on a simple idea: limiting the phenylalanine (Phe) that enters the body.

In practice, this means a highly restrictive diet very low in natural protein, combined with medical protein substitutes also known as amino acid mixtures. The European PKU guidelines still describe this low-phenylalanine diet, with Phe-free amino acid supplementation, as the foundation of treatment. The dietary handbook that accompanies those guidelines also emphasizes the importance of protein substitutes to prevent deficiencies and maintain metabolic control.

This treatment has saved lives. It has helped prevent the most serious neurological consequences of PKU in children diagnosed early. Even today, it remains an essential part of treatment. But we also need to name a reality that people living with PKU know very well: the low-phenylalanine diet is an imperfect crutch.

It does not correct the metabolic problem. Instead, it asks the person to build a large part of life around what the body cannot do. Every meal becomes risky and a calculation. Every deviation has to be assessed. Every outing, every trip, every change in routine can become a negotiation with phenylalanine.

Yes, it is a treatment. But it is also a cognitive, psychological, social, and sometimes financial burden. A study on the financial and time burden of PKU, for example, estimated that families could spend more than 300 hours per year shopping for and preparing special low-Phe foods (Rose et al., 2019). Other work on quality of life in PKU also documents the impact of the disease and its treatment on the daily lives of patients and their families (Bosch et al., 2015).

This burden is every day and does not last a few weeks. This burden lasts a lifetime.

Kuvan: real help, but limited

Kuvan, whose active ingredient is sapropterin, was the first way to move partially beyond a strictly dietary logic.

In some people, sapropterin can help the PAH enzyme work better and reduce blood phenylalanine levels. A Cochrane review concluded that there is evidence of short-term benefit in some people with sapropterin-responsive forms of PKU, including lower Phe levels and a possible increase in natural protein tolerance (Somaraju et al., 2015). But that detail matters: some people.

Kuvan has never worked sufficiently for everyone. For many people with more classic or severe PKU, it has not transformed daily life. The diet has remained the centre of and only form of treatment. Kuvan can help some patients, but it does not always meaningfully reduce the concrete weight of PKU.

This is where Sephience becomes interesting.

Sephience: the direct goal remains lowering Phe

The AMPLIPHY study directly compares Sephience, whose active ingredient is sepiapterin, with sapropterin. In participants who responded to sepiapterin, Sephience lowered phenylalanine more than the highest approved dose of sapropterin. The authors concluded that Sephience was superior to sapropterin in lowering blood Phe, with no new safety signals observed.

The nuance matters: this does not mean Sephience will work for everyone. Response has to be assessed individually. The U.S. prescribing information states that biochemical response generally cannot be predicted by laboratory testing alone and should be determined through a therapeutic evaluation with Phe monitoring (FDA, Sephience Prescribing Information).

But in people who respond, the signal is important.

Sephience should not be presented as a cognitive treatment in the direct sense. Its primary goal is more specific: lowering blood phenylalanine in people who respond to it. This distinction matters.

In PKU, a drop in Phe can be measured relatively quickly. The possible effects of better metabolic control on concentration, mental fatigue, mood, or certain executive functions may take longer to appear, when they appear at all. They also depend on many factors: a person’s metabolic history, age, duration of control, diet, sleep, psychological state, and life context.

It would therefore be reductive to evaluate a PKU treatment only as if it had to produce an immediately visible improvement in daily functioning within a few weeks. The most direct link to evaluate is first the control of phenylalanine. Then comes the slower, but very important, question of what better sustained control can deliver in real life.

This nuance is not theoretical.

In its evaluation of Palynziq, INESSS recognized that PKU causes an accumulation of Phe that is toxic to the brain, that poorly controlled adults may experience neuropsychiatric difficulties, and that the strict diet is difficult to follow. INESSS also noted that Palynziq reduced Phe concentration, but that the 8-week study evaluated did not show improvement in daily functioning or emotional management (INESSS, Palynziq, 2023).

This is exactly where careful interpretation becomes essential. A reduction in Phe is a direct metabolic effect. Possible functional or cognitive impacts may be slower, more variable, and harder or impossible to capture in a short observation window.

In other words: Sephience does not directly “repair” cognition. It aims to reduce the body’s and brain’s exposure to excessive phenylalanine. If that reduction is maintained over time, it may create better conditions for neurological health, quality of life, and a lighter daily burden.

The brain, Phe, and time

Imaging data support the idea that metabolic control can have important neurological implications in PKU, even if we must avoid shortcuts. A study published in 1995 observed that some white matter abnormalities seen on magnetic resonance imaging were at least partially reversible when blood phenylalanine concentration was lowered (Cleary et al., 1995). An important review by Anderson and Leuzzi reached a similar conclusion: white matter pathology in PKU is associated with metabolic control and may be reversible with strict adherence to a low-Phe diet (Anderson and Leuzzi, 2010). More recently, a study in early-treated adults showed that white matter alterations were related to performance in certain attention and executive function tasks (Muri et al., 2023).

These studies do not mean that a medication directly rebuilds white matter. That would be too simple a shortcut. They suggest, rather, that the brain remains affected by the quality of metabolic control, and that Phe should not be treated as just a lab number. In PKU, if a treatment helps keep Phe lower, more often, and for longer, with less effort that is difficult to sustain, it may create better biological conditions. Not a magical promise. Not a guarantee. But a more favourable foundation.

Diet normalization is not a minor detail

One of the most important aspects of Sephience may not be only the reduction in Phe itself, but what that reduction may allow in daily life. In the language of the APHENITY Extension study, the measured outcome is dietary normalization: an increase in dietary Phe tolerance under metabolic monitoring. But from a patient perspective, the broader goal is dietary normalization. Not necessarily the immediate removal of all restrictions, but a meaningful shift toward a normal, less synthetic diet, less medicalized and less life organization around PKU.

In that extension study, participants who reached a mean Phe level below 360 µmol/L after two weeks were able to enter a dietary Phe tolerance assessment phase. Among the 102 participants assessed, mean dietary Phe intake increased from 27.6 mg/kg/day at baseline to 62.5 mg/kg/day at week 26, while blood Phe continued to be monitored and remained within current treatment goals

For a person who has lived with PKU since childhood, eating more normally is not just a secondary comfort. It can mean more natural protein, less dependence on medical products, fewer calculations, less fear around meals, less social isolation, and less decision fatigue. The idea of “normalization” may sound ordinary from the outside. It is not ordinary when food has always been an area of acute surveillance because of the threat of Phe.

Of course, Sephience does not mean the diet disappears. Health Canada’s approved indication states that Sephience is indicated for patients with sepiapterin-responsive PKU in conjunction with a phenylalanine-restricted diet. The Canadian product monograph also specifies that patients treated with Sephience should remain on a Phe-restricted diet as directed by their healthcare provider, based on blood Phe assessment. People will still need to measure, adjust, monitor, and work with a metabolic team. But that does not reduce the importance of the possible change. A treatment can matter even if it does not remove every constraint. It can matter because it shifts the daily burden of treatment, makes metabolic control more realistic, and turns a permanent discipline into something more breathable.

Partager

What Sephience could change

In my view, Sephience should not be evaluated as a fast promise of cognitive improvement. It should first be evaluated for what it does directly: lowering phenylalanine in people who respond. Then comes the slower, but essential, question of what better-controlled Phe can allow over time.

Lower and more stable Phe can support better metabolic stability. Better stability can reduce part of the mental burden. Greater food tolerance can make the diet less invasive. And if, over time, this also allows some people to function better day to day, that would be a possible consequence of better sustained metabolic control, not a simplistic promise.

PKU has never been only about food. It is a metabolic disease that imposes a complete organization of life around phenylalanine. The low-Phe diet remains a foundation. Kuvan has helped some patients. Sephience now seems to open a different possibility: not perfectly bypassing PKU, but reducing more of its grip in people who respond. For someone living with PKU, lowering Phe is not just improving a blood result. It may mean reducing a burden that accumulates meal after meal, year after year.

And if Sephience can do that, even without solving everything, then it may represent much more than a new medication. It may represent a new way of living with phenylketonuria.

Laissez un commentaire.

It’s not often that we’re asked directly for our take on a treatment that could change our daily lives. This time, we are.

INESSS is currently evaluating whether Sephience will be covered by the RAMQ. The Institute is inviting people living with phenylketonuria and their caregivers to submit comments as part of that evaluation.

Why does it matter? Because these comments become part of the file INESSS reviews. Our lived experience, the daily weight of the diet, what it would actually mean to finally have access to this treatment: that’s exactly the kind of information they’re looking for, and that no study can tell in our place. It guarantees nothing. But the more of us who speak up, the more our reality weighs in the balance.

How to take part?

• The deadline is July 7, 2026.

• Fill out the official form « Drug Evaluation - Questionnaire for Patients and Caregivers » (the patient questionnaire, downloadable through the link or button below).

Questionnaire for Patients

• Send it by email to plan.commentaires.inscription@inesss.qc.ca, or by mail to the following address:

Institut national d’excellence en santé et en services sociaux (INESSS)
Direction du médicament
2535, boulevard Laurier, 5e étage
Québec (Québec) G1V 4M3

You're the best placed to speak about your daily life and what phenylketonuria changes for you. That's exactly what INESSS wants to hear, in your own words. If it helps you think through the areas it touches (diet, social life, mental health, cognition), I've written about that. But the testimony that counts is yours, not mine.

We rarely get the chance to speak straight into the mic. Let’s take it. And share this with the people around you: every testimony counts.

Partager

Disclaimer: I’m not a doctor, a researcher, or a healthcare professional. What I share here reflects my reading and my lived experience as someone who lives with phenylketonuria. For any question about your situation or your treatment, talk to your medical team.

Article en français

Key Takeaways:

• Mental burden parallel: The article establishes a link between the constant vigilance required by a low-protein diet in Phenylketonuria (PKU) and the permanent state of alert experienced by patients with Chronic Granulomatous Disease (CGD) due to infection risks.

• Advancements in prime editing: The success of prime editing treatment in Ty Sperle demonstrates that a precise DNA correction technique (acting as a genetic “spell checker”) can stop the symptoms of a rare disease and eliminate the need for daily medication.

• Perspective and caution: While this scientific achievement is a major source of hope for genetic diseases, applying genome editing to the treatment of Phenylketonturia remains a complex technological challenge that is far from being realized in the near future.

Phenylketonuria imposes a massive mental burden on those living with it, affecting many aspects of life, both physiologically and cognitively. Personally, I face various daily obstacles that could easily be avoided if I didn’t constantly have to keep my low-protein diet at the forefront of my mind.

I recently came across an article that reminded me that beyond PKU, there are many rare diseases that have an impact on patients’ lives (if not more) than PKU does. The article discussed the journey of Ty Sperle, a young man living with a condition called Chronic Granulomatous Disease.

But a small technological miracle has come to change his daily life: prime editing.

Chronic Granulomatous Disease and Prime Editing

Ty’s disease imposed a mental burden similar to what we experience with PKU.

In a healthy body, our white blood cells capture and destroy infections, bacteria, or fungi. But in a patient with Chronic Granulomatous Disease, the white blood cells lack the “ammunition” to destroy intruders; consequently, the body can only attempt to isolate them (forming what is known as a granuloma). The multiplication of these granulomas can then obstruct airways, damage the skin, and even affect internal organs.

It is a condition that forces one to live in a constant state of alert, as even the most mundane elements can become dangerous:

• The omnipresence of small bacteria or mold poses a threat.

• Medications are a part of daily life.

• There is a permanent sense of threat and insecurity.

But this year, Ty Sperle became the first person in the world to be cured thanks to prime editing! This method acts as a way to correct “spelling mistakes” in DNA, causing symptoms to disappear. The medications are gone; the mental burden has lifted.

“I also love camping and, you know, it was a risk before, because there are so many bacteria in the woods... so now I can do it without that risk. I was on a regimen of pills and they are all gone, so I no longer need to take medication, which is simply incredible.”
— Ty Sperle

Partager

According much to Ty, his mother was not in the room with him when he learned he was cured, but when he told her, she reacted immediately with tears of joy. I have been reflecting on this story for several days, and I can only imagine the happiness parents of a child with PKU would feel if they were told that a gene-editing technique had cured their child.

We must remain very realistic; such technology is not something that will be working for Phenylketonuria anytime soon. Many challenges, tests, and much future complexity remain before this can become a reality, but it is certainly very encouraging for me to see that this treatment has finally worked in a human being. :)

Laissez un commentaire.

Article en français

Key takeaways

• Sephience could enable many adults with PKU to tolerate more natural proteins and move away from a strictly carbohydrate-based diet.

• Its potential impact could extend beyond diet, affecting quality of life, mental health, certain cognitive functions, and long-term metabolic health.

• The real question now is no longer just scientific: it is one of practical access to treatment.

Health Canada’s approval of Sephience marks a historic moment for people living with phenylketonuria. This treatment could finally ease a burden that has weighed on us since childhood. But until the Canadian Drug Agency (CDA) and the National Institute for Health and Social Services Excellence (INESSS) give their approval, this treatment will remain out of reach. And yet, there are many solid reasons to approve it, backed by science.

Here are five major reasons why Sephience can truly change the life of an adult with PKU, in terms of diet, social life, psychology, cognition, metabolism, and longevity.

1. The low-protein diet is a crutch, and it is no longer enough

The low-protein diet is not sustainable over decades. Adults with PKU know this: it is not just difficult, it is exhausting. And even when you make an effort, your diet becomes unbalanced, too high in carbohydrates, too low in natural proteins, and this is not without consequences.

What the science says

• An integrative review has shown that people with PKU consume excessive amounts of carbohydrates, very little natural protein, and develop problematic nutritional profiles as they age. Study: Dietary intake in individuals with phenylketonuria: an integrative review (2023)

• Another study showed that adults with PKU have an abnormal carbohydrate profile and associated metabolic imbalance. Study: Carbohydrate status in patients with phenylketonuria (2018)

What Sephience enables

By increasing tolerance to natural proteins, Sephience breaks the vicious cycle of “all carbohydrates.” This finally allows for a more realistic, healthier, and more balanced diet, without having to maintain quasi-military discipline throughout one’s life.

2. A simpler and more normal social life

Phenylketonuria can isolate or at least create a feeling of isolation. Refusing dinners, bringing your own food, having to explain your condition over and over again... it’s exhausting. And it ends up driving people away.

What science says

• A qualitative study shows that people living with PKU often feel socially excluded, and that managing their diet is a constant source of anxiety and emotional fatigue. Study: How individuals with phenylketonuria experience their ill

• The psychosocial well-being of PKU families and children is directly influenced by the burden of the diet. Study: Psychosocial functioning in children with PKU (2020)

What Sephience enables

By reducing dietary restrictions, Sephience makes it possible to say “yes” to dinners and invitations. It restores a normal social life and removes a huge burden. An adult with PKU who can share a meal is an adult who can regain their place in society.

3. A tangible improvement in mental health

Variations in Phe directly influence anxiety, irritability, and motivation. This is not a psychological whim: it is biochemical.

What science says

• Emotional well-being is strongly affected by dietary strictness and metabolic control. Study: Psychosocial functioning in children with PKU (2020)

• Adults with PKU describe significant psychological burden, daily stress, and anxiety related to aging. Study: How individuals with phenylketonuria experience their illness (2009)

What Sephience enables

By better stabilizing phenylalanine, Sephience can, in the long term, reduce anxiety, mood swings, and the burden of dieting, in addition to improving factors that affect our mental health. This provides real relief and a return to control over one’s emotional life.

4. Cognition and myelin: protecting the brain and preserving our future

PKU affects processing speed, attention, and cognitive flexibility, even in adults who were treated early.

What the science says

• Adults with PKU show documented cognitive differences, even when they have been treated since birth. Study: Cognitive outcomes in early-treated adults with PKU (2021)

• A meta-analysis shows that executive functions and processing speed are consistently affected in adults with PKU. Study: Meta-analyses of cognitive functions in early-treated adults with PKU (2022)

• Myelin damage may be reversible when phenylalanine is better controlled. Study: eversible white matter changes following a 4-week high phenylalanine exposure (2024)

What Sephience enables

By reducing phenylalanine fluctuations, Sephience creates an environment conducive to protecting executive functions and preserving myelin. It is a direct investment in long-term cognitive health.

5. Health span and aging: preparing for our future

We are the first generation to age in large numbers with PKU. No one knows what decades of high Phe levels will do.

What science says

• PKU patients have a distinct metabolic response and specific biochemical variations during physical exertion. Study: Acute exercise in treated phenylketonuria patients (2015)

• PKU adults are at increased risk of insulin resistance, especially with a diet too rich in carbohydrates. Study: Risk of Developing Insulin Resistance in Adult Subjects with PKU (2023)

What Sephience enables

By increasing protein tolerance, Sephience reduces dependence on starchy foods and carbohydrates that directly contribute to insulin resistance, improves metabolic profile, and protects long-term health. This is not a luxury, it is a preventive strategy that can help improve our health as we age by keeping us out of hospitals.

Partager

Access to Sephience is not a matter of comfort. It is a matter of public health, equity, and dignity. By improving quality of life, cognition, mental health, nutritional balance, and aging, Sephience addresses real, pressing, and documented needs. It’s time to recognize that people with PKU deserve better than to just survive: they deserve to live life to the fullest.

Laissez un commentaire.

See also

• Latest news and results for Sepiapterin, a PTC Therapeutics treatment for phenylketonuria

• A PKU story | Nathan and phenylketonuria: living with an invisible disease on a daily basis

Key Takeaways

• Amino acid formulas are the primary source of protein for people living with phenylketonuria (PKU), since natural proteins contain phenylalanine, an amino acid their body cannot metabolize.

• Starting the day with protein rather than carbohydrates stabilizes blood sugar, reduces insulin spikes and improves the glycemic response to subsequent meals (second meal effect). This is particularly important for adults with PKU, who are at increased risk of insulin resistance due to a diet that is naturally too high in carbohydrates.

• A morning amino acid formula shake (like this chocolate and caramel shake with 50g of protein equivalent) is a concrete strategy for building a solid nutritional foundation from the very start of the day.

Every morning, it’s the same thing. Before coffee, before emails, before anything else, I prepare my amino acid formula for phenylketonuria. 50 grams of protein equivalent, low in carbohydrates. It’s my foundation. It’s what keeps me going.

If you live with phenylketonuria, you know our diet is naturally unbalanced: too many carbohydrates, not enough natural protein. It’s documented. Studies show that adults with PKU consume excessive amounts of carbohydrates and develop problematic nutritional profiles as they age. The risk of insulin resistance is real, and it’s directly linked to that carbohydrate overload in our diet.

But here’s what science also tells us, and this isn’t just about us: starting your day with protein instead of carbohydrates is a complete game changer. A protein-rich breakfast stabilizes blood sugar, reduces insulin spikes and even improves the glycemic response to your next meal. Researchers call it the “second meal effect”: what you eat in the morning directly influences how your body reacts at lunch. And the opposite is also true. A breakfast high in refined carbohydrates causes a rapid blood sugar spike, followed by a crash that brings hunger, irritability and the urge to snack.

For someone with PKU, this is even more critical. We can’t get our protein from eggs or Greek yogurt like everyone else. Our amino acid formulas are our main source. So if I don’t start my day with that, I’m already starting at a deficit. And a protein deficit in the morning, combined with our dependence on starchy foods, is exactly the recipe for the long-term metabolic problems we’re trying to avoid.

Partager

So yes, my morning shake is non-negotiable. It’s my nutritional foundation for the day. And as a bonus, the one I’m sharing with you today tastes like chocolate and caramel.

Ingredients

• About one and a half cups of water (adjust to taste)

• 2 packets of Glytactin Build chocolate amino acid formula

• 1 packet of Phenylade GMP Mix-In

• A few drops of caramel stevia

Preparation

• It’s very simple. Pour the water and ingredients into a blender (or Magic Bullet).

• Blend for 30 seconds.

• Enjoy.

Laissez un commentaire.

Health Canada finally approved PTC Therapeutics’ Sephience in October 2025, a very promising treatment that has already proven itself and has the potential to improve the lives of people with phenylketonuria. But nothing is certain yet!

Make your voice heard: Take CanPKU+’s survey before November 30!

There is no guarantee that it will be made available in all Canadian provinces. It is therefore essential that we share our experiences with PKU, describe our daily challenges, and, above all, explain how Sephience has the potential to significantly change our daily lives. To this end, I invited several members of the community to send me their testimonials. Today, I am sharing Catherine Héroux’s story with you.

Nathan is 9 years old. Like all children his age, he loves to play, laugh, and enjoy life. But Nathan lives with a rare disease: phenylketonuria (PKU). This inherited metabolic disorder prevents his body from properly breaking down phenylalanine, an amino acid found in proteins. To avoid a toxic buildup in his blood, he must follow an extremely strict, low-protein diet every day of his life.

Nathan can consume a maximum of 330 mg of phenylalanine per day, or about 7 grams of protein. Every food he eats must be weighed, measured, and calculated. The slightest deviation can have serious consequences for his neurological development, leading to irreversible cognitive disorders.

On paper, it may seem simple: all you have to do is count. In reality, it’s a daily struggle.

Let’s take an example: a typical breakfast for a 9-year-old child, two slices of toast with Nutella and a banana.

• The bread must contain less than 1 g of protein per slice (45 mg of phenylalanine).

• The banana adds 45 mg.

• A tablespoon of Nutella adds 45 mg.

Result: 135 mg of phenylalanine for breakfast. That leaves him with only 195 mg for the rest of the day. That includes three meals and snacks. The margin is tiny.

Preparing meals, measuring quantities, planning menus, administering the special medical formula... all this takes up nearly 4 hours a day, or 28 hours a week, the equivalent of a part-time job.

There are many frustrations. Some days, Nathan is hungrier than usual. But once he reaches his limit, he only has a few very low-protein foods left, which are often tasteless. Temptations are everywhere: at the grocery store, at school, at friends’ parties, on Halloween, or during class celebrations. These are all moments that remind Nathan that he can’t eat like everyone else.

Beyond the diet, there is the emotional weight. Nathan often asks himself, “Why me?” He is tired of explaining his condition to justify his “different” meals. His need to be accepted, understood, and feel normal is constant.

Going on a trip with a child with PKU is a planning challenge. It’s impossible to rely on the food available at the destination: everything must be prepared in advance, weighed, and transported. Vacation time turns into management and calculation time. Spontaneity does not exist.

Fortunately, science is advancing.

A new drug, Sephience, could transform the lives of people with PKU. This treatment helps reduce blood phenylalanine levels and increases daily protein intake.

For Nathan, this would mean being able to try more foods, go to restaurants, travel more freely, and above all, live like a normal child. This drug represents not only medical hope, but also immense relief for families who spend hours preparing and calculating meals.

When Nathan learned about Sephience, his eyes lit up. For him, it is the promise of a simpler, freer life.

Sephience must become available to residents of Quebec. Every day counts for children like Nathan, who show exceptional courage and resilience. Thanks to science, they can hope for a more normal life. But for that to happen, these advances must be available to everyone.

Let’s give Nathan and all children with phenylketonuria the hope of a life without calculations, without fear, and full of freedom.

Let’s make our voices heard loud and clear

Even when treated with a low-protein diet, phenylketonuria remains a daily challenge: it affects every meal, every decision, every moment of freedom. However, Sephience offers solutions that could lighten this burden and give us back control of our lives.

If you would like to add your testimony to this campaign, please feel free to send it to me. Every story is important. Otherwise, simply share this article to spread the message.

Partager

Many thanks to Catherine Héroux for her testimony.

See also

• Latest news and results for Sepiapterin, a PTC Therapeutics treatment for phenylketonuria

• A CanPKU+ training session | Treatment approved. Now what? Advocacy training session 1